COVER STORY
stated:“ The 25 % penalty and fine are a serious blow to India’ s exports, especially when the US has been our biggest trading partner for years. Pharma and electronics are taking the biggest hit. Beyond monetary, this move adds a layer of uncertainty to an already shaky global trade environment. India isn’ t just a key supplier of generics to the US; we are a part of the backbone of affordable global healthcare. These duties may interrupt the smooth trade flow, inflate US drug costs, stall treatments, and put even greater pressure on American healthcare budgets. Back home, the profits for Indian pharmaceutical firms may decline, and R & D may stagnate, slowing down innovation and stalling new drug clearances.”
“ Since Trump’ s return, the change in trade tone has been clear. It’ s a wakeup call— India must double down on securing Free Trade Agreements with other major economies. These aren’ t just about market access; they’ re about securing India’ s place in the world economy and advancing the vision of a‘ Viksit Bharat’. India needs to act fast, and more importantly, act smart. Clear, confident diplomacy is the need of the hour,” Mariwala added.
Why India matters
India isn’ t a fringe supplier. It supplies the bulk of generic drugs consumed in the U. S.; industry data show Indian manufacturers account for an enormous share of the U. S. generic market by volume. In 2024,
18
BioVoiceNews | September 2025